The JAHA publication is a validation event that reduces regulatory risk for the Phase III MAVERIC trial. Traders should watch for MAVERIC enrollment completion and top-line data readout as the next major catalysts. The stock may see modest positive momentum from this de-risking, but the absence of new data limits upside magnitude.
Price Chart
Executive Summary
Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results for CardiolRx in recurrent pericarditis in the Journal of the American Heart Association (JAHA). The peer-reviewed publication highlights rapid and sustained reductions in pain and inflammation, a favorable safety profile, and supports the ongoing pivotal Phase III MAVERIC trial, which is nearing full enrollment. This is a positive de-risking event for the program but does not provide new clinical data beyond previously presented results.
Key Facts
- Phase II MAvERIC study results published in the Journal of the American Heart Association (JAHA), a top-tier peer-reviewed cardiovascular journal.
- CardiolRx associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with high baseline disease burden.
- Substantial reductions in pericarditis episodes per year reported, along with a favorable safety and tolerability profile.
- Pivotal Phase III MAVERIC trial (NCT06708299) is nearing full patient enrollment.
- CardiolRx has U.S. FDA Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis.
Financial Impact
No financial figures provided in the filing. The event is a clinical milestone with no revenue or earnings data.
Risk Factors
- Phase III MAVERIC trial may fail to replicate Phase II results in a larger, placebo-controlled setting.
- No revenue or near-term commercialization path; company remains pre-revenue with reliance on financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000670 |
| Document: cardiol6k.htm | 0001279569-26-000670 |
| Document: 0001279569-26-000670-index-headers.html | 0001279569-26-000670 |
| Document: 0001279569-26-000670-index.html | 0001279569-26-000670 |
| Document: 0001279569-26-000670.txt | 0001279569-26-000670 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.14 (−35.59%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.14 (−35.59%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.14 (−40.00%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.14 (−42.86%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.14 (−42.86%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.14 (−50.11%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.14 (−14.93%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.14 (−0.87%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.14 (+14.92%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.14 (−12.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers